Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab

Divyanshu Dubey, Christopher A. Cano, Olaf Stuve

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the manage­ment of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical develop­ment in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS.

Original languageEnglish (US)
Pages (from-to)2405-2414
Number of pages10
JournalNeuropsychiatric Disease and Treatment
Volume11
StatePublished - Sep 18 2015
Externally publishedYes

Fingerprint

Multiple Sclerosis
Safety
Antibodies, Monoclonal, Humanized
Phase III Clinical Trials
Graft vs Host Disease
B-Cell Chronic Lymphocytic Leukemia
United States Food and Drug Administration
Bone Marrow Transplantation
Kidney Transplantation
History
Physicians
alemtuzumab
Pharmaceutical Preparations

Keywords

  • Alemtuzumab
  • CD52
  • Idiopathic thrombocytopenic purpura
  • Monoclonal antibody
  • Multiple sclerosis

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab. / Dubey, Divyanshu; Cano, Christopher A.; Stuve, Olaf.

In: Neuropsychiatric Disease and Treatment, Vol. 11, 18.09.2015, p. 2405-2414.

Research output: Contribution to journalReview article

@article{2dcdecbc720a43febb84be0f12e42af7,
title = "Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab",
abstract = "Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the manage­ment of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical develop­ment in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS.",
keywords = "Alemtuzumab, CD52, Idiopathic thrombocytopenic purpura, Monoclonal antibody, Multiple sclerosis",
author = "Divyanshu Dubey and Cano, {Christopher A.} and Olaf Stuve",
year = "2015",
month = "9",
day = "18",
language = "English (US)",
volume = "11",
pages = "2405--2414",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Intractable and highly active relapsing multiple sclerosis – Role of alemtuzumab

AU - Dubey, Divyanshu

AU - Cano, Christopher A.

AU - Stuve, Olaf

PY - 2015/9/18

Y1 - 2015/9/18

N2 - Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the manage­ment of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical develop­ment in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS.

AB - Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the manage­ment of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical develop­ment in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS.

KW - Alemtuzumab

KW - CD52

KW - Idiopathic thrombocytopenic purpura

KW - Monoclonal antibody

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84942317156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942317156&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84942317156

VL - 11

SP - 2405

EP - 2414

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -